Skip to main content


Fig. 3 | Radiation Oncology

Fig. 3

From: A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma

Fig. 3

Treatment Response and Survival. a Abdominal and b thoracic coronal CT slices from patient 11 pre-SABR (left) and 7 months post-SABR (right). c Tumour size expressed as percent change in longest tumour dimension. Horizontal dotted lines mark a 20% increase and 30% decrease in size. Patient 9 (dotted/dashed line) also underwent renal embolization for refractory hematuria on day 27 post-SABR. d Kaplan-Meier plot of overall survival with 95% confidence bands (n = 12)

Back to article page